A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1
CJ Petropoulos, NT Parkin, KL Limoli… - Antimicrobial agents …, 2000 - Am Soc Microbiol
Although combination antiretroviral therapy has resulted in a considerable improvement in
the treatment of human immunodeficiency virus (HIV) type 1 (HIV-1) infection, the emergence …
the treatment of human immunodeficiency virus (HIV) type 1 (HIV-1) infection, the emergence …
Rapid evolution of the neutralizing antibody response to HIV type 1 infection
…, T Wrin, SJ Little, CJ Petropoulos - Proceedings of the …, 2003 - National Acad Sciences
A recombinant virus assay was used to characterize in detail neutralizing antibody responses
directed at circulating autologous HIV in plasma. Examining serial plasma specimens in a …
directed at circulating autologous HIV in plasma. Examining serial plasma specimens in a …
[PDF][PDF] Multiple early factors anticipate post-acute COVID-19 sequelae
…, RA Cochran, ME Micikas, T Wrin, CJ Petropoulos… - Cell, 2022 - cell.com
Post-acute sequelae of COVID-19 (PASC) represent an emerging global crisis. However,
quantifiable risk factors for PASC and their biological associations are poorly resolved. We …
quantifiable risk factors for PASC and their biological associations are poorly resolved. We …
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
…, S Zolla-Pazner, H Katinger, CJ Petropoulos… - Journal of …, 2004 - Am Soc Microbiol
Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …
immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been …
[HTML][HTML] Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia
…, NS Hellmann, CJ Petropoulos… - … England Journal of …, 2001 - Mass Medical Soc
Background In many patients with human immunodeficiency virus (HIV) infection, therapy
with potent antiretroviral drugs does not result in complete suppression of HIV replication. The …
with potent antiretroviral drugs does not result in complete suppression of HIV replication. The …
Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism
…, LDB Kiss, EE Paxinos, CJ Petropoulos - Antimicrobial agents …, 2007 - Am Soc Microbiol
Most human immunodeficiency virus type 1 (HIV-1) strains require either the CXCR4 or CCR5
chemokine receptor to efficiently enter cells. Blocking viral binding to these coreceptors is …
chemokine receptor to efficiently enter cells. Blocking viral binding to these coreceptors is …
Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors
SH Hughes, JJ Greenhouse, CJ Petropoulos… - Journal of …, 1987 - Am Soc Microbiol
We have previously described several helper independent vector constructions (S. Hughes
and E. Kosik, Virology 136:89-99, 1984; J. Sorge and SH Hughes, J. Mol. Appl. Genet. 1:547-…
and E. Kosik, Virology 136:89-99, 1984; J. Sorge and SH Hughes, J. Mol. Appl. Genet. 1:547-…
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
…, Z Lu, D Cohen, T Wrin, CJ Petropoulos… - The Journal of …, 2008 - academic.oup.com
Background. Spontaneous control of human immunodeficiency virus (HIV) infection has
been documented in a minority of HIV-infected individuals. The mechanisms behind this …
been documented in a minority of HIV-infected individuals. The mechanisms behind this …
Markers of immune activation and inflammation in individuals with postacute sequelae of severe acute respiratory syndrome coronavirus 2 infection
…, BC Yee, JW Winslow, CJ Petropoulos… - The Journal of …, 2021 - academic.oup.com
Background The biological processes associated with postacute sequelae of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) are unknown. Methods …
Time trends in primary HIV-1 drug resistance among recently infected persons
…, M Warmerdam, L Liu, T Liegler, CJ Petropoulos… - Jama, 2002 - jamanetwork.com
ContextTransmission of multiclass drug-resistant human immunodeficiency virus type 1 (HIV-1)
may increase with wider use of antiretroviral therapy.ObjectiveTo determine trends in …
may increase with wider use of antiretroviral therapy.ObjectiveTo determine trends in …
